Nesiritide Administration in Patients With Left Ventricular Dysfunction Undergoing Coronary Artery Bypass Surgery**Editorials published in the Journal of the American College of Cardiology reflect the views of the authors and do not necessarily represent the views of JACC or the American College of Cardiology.

Journal of the American College of Cardiology

Volumn 49, Issue 6, 2007, Pages 727-728

  Belenkie, Israel ^a  

^a UNIVERSITY OF CALGARY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

GLYCERYL TRINITRATE; NESIRITIDE; VASODILATOR AGENT;

ANESTHESIA INDUCTION; BLOOD PRESSURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY BYPASS SURGERY; DRUG DOSE TITRATION; DRUG EFFECT; DRUG SAFETY; EDITORIAL; GLOMERULUS FILTRATION RATE; HEART EJECTION FRACTION; HEART LEFT VENTRICLE FAILURE; HOSPITALIZATION; HUMAN; HYPOTENSION; KIDNEY FUNCTION; KIDNEY PERFUSION; LOW DRUG DOSE; PRIORITY JOURNAL; RENAL PROTECTION; SCREENING; SIDE EFFECT; TREATMENT OUTCOME; URINE VOLUME;

CORONARY ARTERY BYPASS; HEART FAILURE, CONGESTIVE; HUMANS; KIDNEY; NATRIURETIC AGENTS; NATRIURETIC PEPTIDE, BRAIN; VENTRICULAR DYSFUNCTION, LEFT;

EID: 33846813585     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jacc.2006.11.009     Document Type: Editorial

References (21)

1. Burger A.J. A review of the renal and neurohormonal effects of B-type natriuretic peptide. Congest Heart Fail 11 (2005) 30-38
2. Adams Jr. K.F., Mathur V.S., and Gheorghiade M. B-Type natriuretic peptide: from bench to bedside. Am Heart J 145 (2003) S34-S46
3. de Lemos J.A., McGuire D.K., and Drazner M.H. B-type natriuretic peptide in cardiovascular disease. Lancet 362 (2003) 316-322
4. Colucci W.S., Elkayam U., Horton D.P., and Nesiritide Study Group. Intravenous nesiritide, a natriuretic peptide, in the treatment of decompensated congestive heart failure. N Engl J Med 343 (2000) 246-253
5. Publication Committee for the VMAC Investigators. Intravenous nesiritide vs nitroglycerin for treatment of decompensated congestive heart failure. JAMA 287 (2002) 1531-1540
6. Mills R.M., Horton D.P., and LeJemtel T.H. Sustained hemodynamic effects of an infusion of nesiritide (human B-type natriuretic peptide) in heart failure: a randomized, double-blind, placebo-controlled clinical trial. J Am Coll Cardiol 34 (1999) 155-162
7. Marcus L.S., Hart D., and Packer M. Hemodynamic and renal excretory effects of human brain natriuretic peptide infusion in patients with congestive heart failure. Circulation 94 (1996) 3184-3189
8. Michaels A.D., Chatterjee K., and de Marco T. Effects of intravenous nesiritide on pulmonary vascular hemodynamics in pulmonary hypertension. J Card Fail 11 (2005) 425-431
9. Protter A.A., Wallace A.M., Ferraris V.A., and Weishaar R.E. Relaxant effect of human brain natriuretic peptide on human artery and vein tissue. Am J Hypertens 9 (1996) 432-436
10. Jensen K.T., Eiskjaer H., Carstens J., and Pedersen E.B. Renal effects of brain natriuretic peptide in patients with congestive heart failure. Clin Sci (Lond) 96 (1999) 5-15
11. Abraham W.T., Lowes B.D., Ferguson D.A., et al. Systemic hemodynamic, neurohormonal, and renal effects of a steady-state infusion of human brain natriuretic peptide in patients with hemodynamically decompensated heart failure. J Card Fail 4 (1998) 37-44
12. Aronson D., and Burger A.J. Intravenous nesiritide (human B-type natriuretic peptide) reduces plasma endothelin-1 levels in patients with decompensated congestive heart failure. Am J Cardiol 90 (2002) 435-438
13. Sackner-Bernstein J.D., Kowalski M., Fox M., and Aaronson K. Short-term risk of death after treatment with nesiritide for decompensated heart failure: a pooled analysis of randomized controlled trials. JAMA 293 (2005) 1900-1905
14. Mentzer Jr. R.M., Oz M.C., Sladen R.N., et al., NAPA Investigators. Effects of perioperative nesiritide in patients with left ventricular dysfunction undergoing cardiac surgery: the NAPA trial. J Am Coll Cardiol 49 (2007) 716-726
15. Abraham W.T., Adams K.F., Fonarow G.C., et al. In-hospital mortality in patients with acute decompensated heart failure requiring intravenous vasoactive medications: an analysis from the Acute Decompensated Heart Failure National Registry (ADHERE). J Am Coll Cardiol 46 (2005) 57-64
16. Silver M.A., Horton D.P., Ghali J.K., and Elkayam U. Effect of nesiritide versus dobutamine on short-term outcomes in the treatment of patients with acutely decompensated heart failure. J Am Coll Cardiol 39 (2002) 798-803
17. Abraham W. Serum creatinine elevations in patients receiving nesiritide are related to starting dose. (abstr). J Card Fail 11 (2005) S156
18. Chen H.H., Grantham J.A., Schirger J.A., Jougasaki M., Redfield M.M., and Burnett Jr. J.C. Subcutaneous administration of brain natriuretic peptide in experimental heart failure. J Am Coll Cardiol 36 (2000) 1706-1712
19. Riter H.G., Redfield M.M., Burnett J.C., and Chen H.H. Nonhypotensive low-dose nesiritide has differential renal effects compared with standard-dose nesiritide in patients with acute decompensated heart failure and renal dysfunction. J Am Coll Cardiol 47 (2006) 2334-2335
20. Heywood J.T. Combining nesiritide with high-dose diuretics may increase the risk of increased serum creatinine. (abstr). J Card Fail 11 (2005) S154
21. Sackner-Bernstein J.D., Skopicki H.A., and Aaronson K.D. Risk of worsening renal function with nesiritide in patients with acutely decompensated heart failure. Circulation 111 (2005) 1487-1491